Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2016Clinical ChemistryOpen Access

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does pharmacogenetic testing improve health outcomes in patients treated with cardiovascular drugs?

Design

Review

Authors

KFKevin A. FriedeJLJosephine H. LiDVDeepak Voora

Discussion

Loading...

Member takes

Overview

Genetic variants shape cardiovascular drug responses; leaves open translation to genotype-guided prescribing.

Structured PICO

Does pharmacogenetic testing improve health outcomes in patients treated with cardiovascular drugs?

I
Intervention
Pharmacogenetic testing for cardiovascular drugs (statins, platelet P2Y12 inhibitors, and anticoagulants)

While genetic variants affect responses to cardiovascular drugs, further evidence is needed before pharmacogenetic testing can be successfully implemented into routine clinical practice.

Limitations

  • Difficulty in implementing cost-effective, point-of-care tools
  • Lack of data demonstrating the efficacy of using genetic information to improve health

Cite This Study

Friede et al. (2016) studied this question.

synapsesocial.com/papers/6a736b49f9fb99ee2c566507https://doi.org/10.1373/clinchem.2016.255232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Application of Cardiovascular Pharmacogenetics2012 · 69 citations
  2. 2Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk2023 · 17 citations
  3. 3Genetic determinants of response to cardiovascular drugs2012 · 21 citations
  4. 4Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art2022 · 29 citations
  5. 5Pharmacogenomics: Application to the Management of Cardiovascular Disease2011 · 58 citations